Document Classification

Section Type: RESULTS

Text: The stratified hazard ratio of PFS for the bevacizumab-containing arm (n = 49) relative to the bortezomib monotherapy arm (n = 53) was 0. 743 (95 % confidence interval [CI], 0. 43-1. 28 ; P =. 2804) ; the median PFS was 6. 2 months (95 % CI, 4. 4-8. 5 months) and 5. 1 months (95 % CI, 4. 2-7. 2 months), respectively ; the overall response rates were 51 % and 43. 4 % (P =. 4029), respectively ; and the median response duration was 6. 9 months (95 % CI, 4. 73-11. 83 months) and 6. 0 months (95 % CI, 4. 86-8. 31 months), respectively.